SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
  • 2
    Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 2005; 92: 2076-2083.
  • 3
    Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011; 47: 1928-1937.
  • 4
    Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003; 2: 4.
  • 5
    Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008; 134: 981-987.
  • 6
    McWilliams RR, Matsumoto ME, Burch PA, et al. Obesity adversely affects survival in pancreatic cancer patients. Cancer. 2010; 116: 5054-5062.
  • 7
    Busaidy N, Yazbeck C, Shah P, et al. Survival of resectable pancreatic cancer patients with diabetes. J Clin Oncol. 2006; 24(18 suppl): abstract 4098.
  • 8
    Chu CK, Mazo AE, Goodman M, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010; 17: 502-513.
  • 9
    Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001; 6: 50-54.
  • 10
    Olowokure O, Beg M, Ali S, et al. Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)? J Clin Oncol. 2010; 28(15 suppl): abstract 4114.
  • 11
    Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas. 2011; 40: 931-937.
  • 12
    Ganti AK, Potti A, Koch M, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: a series of 308 cases. Med Oncol. 2002; 19: 233-237.
  • 13
    Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer. 2010; 127: 2412-2419.
  • 14
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991; 302: 766-768.
  • 15
    Lewis JD, Schninnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007; 16: 393-401.
  • 16
    Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in the health improvement network. Pharmacoepidemiol Drug Saf. 2009; 18: 730-736.
  • 17
    Hall GC. Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf. 2009; 18: 120-131.
  • 18
    Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabetic Med. 2006; 23: 516-521.
  • 19
    Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the general practice research database. Pharmacoepidemiol Drug Saf. 2005; 14: 443-451.
  • 20
    Charlson ME, Pompei P, Ales KA, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 21
    Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989; 129: 125-137.
  • 22
    Wolpin BM, Meyerhardt JA, Chan AT, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009; 27: 176-185.
  • 23
    Fisher WE, Muscarella P, Boros LG, Schirmer WJ. Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the syrian hamster and nude mouse. Surgery. 1998; 123: 315-320.
  • 24
    Fisher WE, Boros LG, O'Dorisio TM, O'Dorisio MS, Schirmer WJ. GI hormonal changes in diabetes influence pancreatic cancer growth. J Surg Res. 1995; 58: 754-758.
  • 25
    Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: Evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996; 63: 310-313.
  • 26
    Feng Y, Busaidy N, Yeung S. Differential impact of anti-diabetic treatment on pancreatic cancer cell growth in cell culture conditions mimicking different stages in the natural history of diabetes mellitus type 2. J Clin Oncol. 2008; 26(15 suppl): 4640.
  • 27
    Jimenez R, Fernández-del Castillo C. Pancreatic cancer. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 9th ed. Mark Feldman M, Friedman LS, Brandt LJ, eds. Philadelphia, PA: Saunders/Elsevier; 2010: 1017-1034.
  • 28
    Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national health and nutrition examination survey 1999-2002. Diabetes Care. 2006; 29: 1263-1268.
  • 29
    Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009; 32: 287-294.
  • 30
    Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009; 32: 2225-2229.